About Illuminox™ Platform
The Illuminox™ platform is a name of an investigational treatment platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is currently developing the Illuminox™ platform as a technology consisting of an investigational drug, device and other related components.
The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding. The device component consists of a light source that locally illuminates the targeted cells with non-thermal light to transiently activates the drug.
*Illuminox™ therapies have not yet been approved as safe or effective by any regulatory authority.
Description of treatment under Illuminox™ Platform
Patients receiving an investigational treatment based on the Illuminox™ platform are first administered with the drug component.
The drug is allowed time to bind to the targeted cells
A non-thermal light dose is applied with a device that then transiently activates the drug component.
By illuminating the targeted cells with non-thermal light, it activates the rapid and selective necrosis with minimal effects on surrounding tissue.
What can the Illuminox™ platform bring forth?
Rakuten Medical is studying potential therapies using Illuminox™ technologies for cancer. Research is currently underway utilizing the Illuminox™ platform to explore the stimulation of the immune system against cells by rapid and selective cell necrosis, resulting not only in a local effect but a systemic one.